• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Merus N.V. - Common Shares (NQ: MRUS )

    43.10 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 164
    Open 43.10
    Bid (Size) 17.24 (2)
    Ask (Size) 47.89 (2)
    Prev. Close 43.10
    Today's Range 43.10 - 43.10
    52wk Range 27.11 - 61.61
    Shares Outstanding 46,530,884
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
    From Merus N.V.
    Via GlobeNewswire
    Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
    From Merus N.V.
    Via GlobeNewswire

    Performance

    YTD
    +50.59%
    +50.59%
    1 Month
    -6.04%
    -6.04%
    3 Month
    -8.67%
    -8.67%
    6 Month
    -28.41%
    -28.41%
    1 Year
    +50.86%
    +50.86%

    More News

    Read More
    Merus Scores Its First FDA Approval For Lung Cancer Drug
    Via Benzinga
    Exposures Product Safety
    Jim Cramer: This Health Care Stock Is 'Very, Very Speculative'
    Via Benzinga
    Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
    From Merus N.V.
    Via GlobeNewswire
    Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
    Via Benzinga
    XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
    From Merus N.V.
    Via GlobeNewswire
    This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    Merus to Present at Upcoming Investor Conferences
    From Merus N.V.
    Via GlobeNewswire
    Merus Receives FDA extension of PDUFA for zenocutuzumab
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024
    From Merus N.V.
    Via GlobeNewswire
    Merus to Present at Canaccord Genuity’s 44th Annual Growth Conference
    From Merus N.V.
    Via GlobeNewswire
    MRUS Stock Earnings: Merus Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
    From Merus N.V.
    Via GlobeNewswire
    Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
    From Merus N.V.
    Via GlobeNewswire
    Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Pricing of Upsized Public Offering of Common Shares
    From Merus N.V.
    Via GlobeNewswire
    Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
    From Merus N.V.
    Via GlobeNewswire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.